NEXTMARINE STAKEHOLDERS MAP

NEXT MARINE — Stakeholder Intelligence Map v1.6
NEXT MARINE NEXT MARINE
Horizon Europe · GA 101181415 · Start: November 2025
Stakeholder Intelligence Map
D6.1 PDEC v1.6 — WP6 Lead: EuroMarine Network (EM)
Stakeholder Priority Matrix
Influence on Key Exploitable Results (KERs) × Ease of engagement — hover any stakeholder for details
51
Stakeholders Mapped
12
EU Institutions
18
National Agencies
4
Target Sectors
↑ Influence / Impact on KERs ↑
GqU4bNnVzf6OKEzIqSCqkCl+oATw3iDpohlyukUrlIIq8Sy4Sf8kpppUj5X4vEcqlM3rAD4gEaFcQdGqOSMklSaml0bFFSUnFpKVbmAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3HTjA54AAALmSURBVAEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAxC3AEAGIS4AwAwCHEHAGAQ4g4AwCDEHQCAQYg7AACDEHcAAAYh7gAADELcAQAYhLgDADAIcQcAYBDiDgDAIMQdAIBBiDsAAIMQdwAABiHuAAAMQtwBABiEuAMAMAhxBwBgEOIOAMAgxB0AgEGIOwAAgxB3AAAGIe4AAAz6H+XCb7l1LULOAAAAAElFTkSuQmCC
🎯 Top Priority — High influence, easy access
B0fGe79E3GkNAAAAAElFTkSuQmCCPharma / KER1
EMA EFPIA EuropaBio JRC Novonesis
QcLsAAAAASUVORK5CYII=Food & Nutrition / KER2–3
EFSA FoodDrinkEurope EABA AMFEP
PzU3R9OsAzj7gDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAI6P8BhgNliYohcrAAAAAASUVORK5CYII=Biopackaging / KER2–3
European Bioplastics CP Kelco
🏛 EU Policy / Institutions
DG SANTE DG MARE
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
💎 Strategic Effort — High influence, complex access
B0fGe79E3GkNAAAAAElFTkSuQmCCPharma corporates
Bayer AG Lonza DSM-Firmenich EPO
PzU3R9OsAzj7gDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAIiLgDgICIOwAI6P8BhgNliYohcrAAAAAASUVORK5CYII=Biomaterials corporates
Novamont Corbion
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 / Regulatory
ECHA Cargill CBD Secretariat Mission Ocean Board
WEVgaLs92pZpgAAAABJRU5ErkJggg==
🌱 Amplifiers — Moderate influence, easy access
EMBRC JERICO-RI DG RTD DG GROW EP ITRE ESSNA EFFCA DECHEMA BlueInvest WWF / Seas At Risk BIO International TERMIS / Biomaterial Soc.
⏳ Monitoring — Lower short-term priority
Medicines for Europe EHPM EP ENVI Committee EP PECH EP SANT EEA NatureWorks / TotalCorbion IAM Magazine
Harder to engage / longer access cycles · Easier to engage / direct relationship
← Strategic effort / long corporate cycles Consortia, conferences, open events →
Pharmaceutical (KER1)
Food & Nutrition (KER2/KER3)
Biomaterials & Biopackaging (KER2/KER3)
Policy & Regulatory (KER7)
Cross-sector
EU Stakeholder & Industry Map
Regulators · industry actors · associations by EU country — click a country to explore strategic targets and their relevance to NEXT MARINE KERs
Atlantic Ocean Mediterranean Sea North Sea FR DE NL BE ES IT GR DK SE SK PL AT IE PT FI CZ HU EMA EFSA ECHA EPO EC ★ JRC Novonesis Strategic Density Very high (EU agencies + industry) High Moderate Lower ● = EU Agency headquarters
EMA (NL) — Pharma/APIs
EFSA (IT) — Food enzymes
ECHA (FI) — REACH/CLP
EPO (DE) — Patents
EC (BE) — DG MARE/RTD
Novonesis HQ (DK) — Key enzyme licensor
Select a country
Click on the map to view national agencies and their relevance to NEXT MARINE KERs
Key Actors by Sector
Regulators · Federations · Lobbies · Target companies — primary webinar and engagement audiences
Pharma
Pharmaceutical
KER1 — Halogenases · Enzyme-enabled API synthesis
Regul.
EMA — European Medicines Agency
Amsterdam. Innovation Task Force open to HE projects. ATMPs, biologicals, enzyme-based APIs. CHMP/CAT scientific committees. Contact ITF from M12 (October 2026) for KER1.
Regul.
EPO — European Patent Office
Munich. Patent filing and landscape monitoring for halogenases (KER1). Freedom-to-operate analysis coordinated by JLU (WP7) from M6 (April 2026).
Fed.
EFPIA
Pan-EU pharma federation (40+ national associations). Innovation Forums = primary dissemination channel for KER1 halogenase discoveries.
Fed.
EuropaBio — Industrial Biotech WG
EU biotechnology association. Industrial Biotech WG = direct audience for KER4 metagenomics pipeline and KER6 bioprocesses.
Lobby
BIO International Organization
Global biotech trade org. BIO Convention for business development and licensing outreach for KER1 APIs.
Corp.
Bayer AG / Sanofi / Lonza / Evonik
Target pharma licensees for halogenase-enabled APIs. Engage from M18 (April 2027)+ after solid PoC and patent filing.
Corp.
Novonesis / DSM-Firmenich / AB Enzymes
World-leading industrial enzyme producers. Primary licensing or co-development partners across KER1–KER6.
Food
Food, Nutrition & Seaweed
KER2 — Alginate lyases / fucoidan · KER3 — Chitinases
Regul.
EFSA — European Food Safety Authority
Parma. Safety opinions on food enzyme preparations (Reg. EC 1332/2008) and novel food (Reg. EU 2015/2283). Core dossier pathway for KER2/KER3. Process ~2 years.
Fed.
FoodDrinkEurope
Main EU food & drink industry association. Engages EFSA panels. Direct channel for enzyme positioning (KER2/KER3) to the food processing industry.
Fed.
EABA — European Algae Biomass Association
Seaweed sector directly impacted by KER2. Annual conferences. Priority webinar audience for alginate lyase and fucoidan enzyme results.
Fed.
EFFCA / ESSNA / AMFEP
Food enzyme and specialty ingredient associations. Members are early adopters of KER2/KER3 enzyme preparations. Active EFSA/ECHA lobbying network.
Lobby
EFF — European Federation of Food S&T
Scientific-industry bridge. Joint position papers on sustainable marine-derived food enzymes. Co-organised webinars from M12 (October 2026).
Corp.
CP Kelco / Algaia / Olmix / Corbion
Direct end-users of KER2 enzyme systems. Pilot partners for WP5. CP Kelco and Algaia = alginates. Corbion = fermentation scale-up and bio-based materials.
Biopackaging
Biomaterials & Biopackaging
KER2/KER3 — Chitosan · Alginate biopolymers · D5.7 Packaging
Regul.
ECHA — European Chemicals Agency
Helsinki. REACH/CLP for chitosan derivatives and industrial enzyme preparations. Unavoidable for KER3/KER6 market entry in biomaterials and biopackaging. Long pathway ~3 years.
Fed.
European Bioplastics (EUBP)
Association for bio-based and biodegradable plastics (100+ member companies). Chitosan and alginate-derived biopolymers (KER2/KER3) are priority feedstocks for bio-based packaging innovations.
Fed.
DECHEMA / TERMIS
Chemical engineering biotech society and tissue engineering society. Biotrans + Biocat conferences for KER1–KER6 results. Chitosan/alginate wound-care and tissue engineering dissemination.
Fed.
AMFEP — Enzyme Producers Association
EU enzyme lobby with direct EFSA/ECHA interface. Positions KER2–KER6 as EU-compliant enzyme preparations. Key for regulatory strategy.
Corp.
Novamont / NatureWorks / TotalCorbion PLA
European bioplastics leaders. Novamont (Mater-Bi), NatureWorks (Ingeo PLA), TotalCorbion — primary targets for marine-derived biopolymer licensing (KER2/KER3). Target M24 (October 2027)+.
Corp.
VITO / Corbion / Biocatalysts Ltd
VITO = consortium member! Industrial enzyme producers and early adopters for KER4/KER6 process applications. Corbion bridges food and packaging markets for alginate applications.
Industrial Biotech
Industrial Biotech & Metagenomics
KER4–KER6 — Metagenomics · Bioprocesses · Scale-up
Regul.
ECHA — European Chemicals Agency
Helsinki. REACH/CLP registration for industrial enzyme preparations (KER4, KER6). Mandatory for scale-up to industrial markets. Coordination from M18 (April 2027).
Fed.
EuropaBio — Industrial Biotech Working Group
Primary EU platform for industrial biotechnology policy and networking. KER4 (metagenomics pipeline) and KER6 (bioprocess scale-up) directly aligned with their advocacy agenda.
Fed.
DECHEMA
Society for Chemical Engineering & Biotechnology. Biotrans + Biocat conferences = primary scientific dissemination venues for KER1–KER6. Enzyme immobilisation and bioprocess WGs.
Fed.
CEFIC — European Chemical Industry Council
EU chemical industry federation. Bioeconomy task force. Green enzyme chemistry pathways (KER1/KER4). Bridge between chemical and biotech sectors for sustainable production.
Corp.
VITO / AB Enzymes / Biocatalysts Ltd
VITO = consortium member! Industrial enzyme producers and early adopters for KER4/KER6 process applications. AB Enzymes (ABF group) = commercial enzyme partner.
Corp.
Novonesis / DSM-Firmenich / Lonza
World enzyme market leaders. Primary licensing targets for the full KER portfolio. Engagement from M18 (April 2027)+ once solid data and IP filings are in place.
Webinar & Engagement Strategy
6 targeted sector events — M9 to M36 — project start: November 2025; M6 = April 2026
Regulatory · Priority 1
EU Regulatory Landscape for Marine Enzymes
Target guests: EFSA (Food Enzyme Panel) · ECHA (REACH/Biocides unit) · AMFEP · FoodDrinkEurope

Goal: Map regulatory pathways for marine enzyme preparations, position NEXT MARINE as an evidence contributor to EFSA, and establish contacts for KER2/KER3 dossiers.
M9–M12 (Jul–Oct 2026)
Pharmaceutical · Priority 2
Halogenases: New Frontiers in Biocatalytic Drug Synthesis
Target guests: EFPIA Innovation Forum · EuropaBio · Lonza · Evonik Life Sciences · Bayer Pharma R&D

Goal: Demonstrate KER1 value for API synthesis, open licensing discussions, identify co-development partners for M24 (October 2027)+ exploitation phase.
M12–M18 (Oct 2026–Apr 2027)
Food & Seaweed · Priority 2
Seaweed Biorefinery: Enzyme-Powered Marine Ingredients
Target guests: EABA · FoodDrinkEurope · CP Kelco · Algaia · Corbion · EFFCA · ESSNA

Goal: Position KER2 (alginate lyases, fucoidan) as key enabling technology for the EU seaweed value chain; generate WP5 pilot partnerships.
M12–M18 (Oct 2026–Apr 2027)
Biomaterials & Biopackaging · Priority 3
Marine Biopolymers: From Deep-Sea to Bio-Based Packaging
Target guests: European Bioplastics · Novamont · Corbion · TERMIS · DECHEMA · VITO

Goal: Introduce chitosan and alginate-derived biopolymers (KER2/KER3) as next-generation feedstocks for biomaterials and bio-based packaging; outline ECHA compliance pathway.
M18–M24 (Apr–Oct 2027)
Policy & Governance · Priority 3
Responsible Marine Bioprospecting: ABS, UNCLOS & Beyond
Target guests: EC DG MARE · CBD Secretariat · Mission Ocean Board · WWF · EEA · EP ENVI Committee

Goal: Present KER7 bioprospecting guidelines; influence ABS/Nagoya regulatory framework; place NEXT MARINE on the ocean governance policy agenda (D6.6).
M24–M30 (Oct 2027–Apr 2028)
Industrial Biotech · Priority 4
Scale-Up & Commercial Exploitation of Marine Enzymes
Target guests: EuropaBio · DECHEMA · Novonesis · ECHA (info session) · BlueInvest

Goal: Present the full KER4–KER6 industrial biotech toolbox; open licensing discussions with industrial enzyme producers; feed into the Commercial Roadmap (D6.8).
M30–M36 (Apr–Oct 2028)
📅 Engagement Timeline — M1 (Nov 2025) to M48 (Oct 2029)
M1
Nov 2025 ✓
M6
Apr 2026 · D6.1
M9–12
Webinar #1
M12–18
Pharma / Food
M18–24
Biopack · D6.3
M24–30
Policy · D6.6
M30–36
Industrial · D6.4
M48
D6.5/D6.7/D6.8

NEXTMARINE — Stakeholder Network Graph

NEXTMARINE — Stakeholder Network

43 organisations · 7 KERs · 5 sectors
v1.6 · 2026
Sector
KER
Sectors
Policy & Regulation
Pharma & Biotech
Food & Nutrition
Cross-cutting
Bioplastics & Biopack
Hubs
KER nodes

Subscribe To The Newsletter

Receive updates on NEXTMARINE expeditions, results and events – four times a year.